新闻

RapAdmin

Aerobic exercise alters the cargo of circulating extracellular vesicles by enriching them with the microRNA-29 family. When these vesicles are delivered to aged osteoarthritic joint cartilage, they counteract tissue stiffness by epigenetically de-repressing the longevity gene Klotho and dampening integrin signaling. This molecular cascade restores a youthful cellular state and reduces physical cartilage degeneration, highlighting a quantifiable and non-pharmacological pathway to joint rejuvenation.

Physical activity is known to offer systemic longevity benefits, but the precise signaling mechanisms reaching avascular tissues like cartilage have remained elusive. This research demonstrates that extracellular vesicles act as systemic delivery vehicles for exercise-induced molecular signals. The researchers utilized a systems biology approach to identify that aerobic exercise loads circulating extracellular vesicles with microRNA-29a-3p and microRNA-29b-3p. Osteoarthritis is largely driven by age-related stiffening of the extracellular matrix. When aged chondrocytes are exposed to a stiff matrix, they undergo pathological morphological changes driven by mechanotransduction, which subsequently locks down the longevity-associated KL (Klotho) gene via promoter hypermethylation. Exercise-primed extracellular vesicles deliver microRNA-29 directly to these cells, which suppresses integrin (ITGB1) signaling. This interruption halts the mechanotransduction cascade, reduces the presence of the DNA methyltransferase DNMT1, and removes the epigenetic block on the Klotho promoter. The result is a reversal of the aged, catabolic cellular phenotype into an anabolic, youthful state. Furthermore, injecting post-exercise extracellular vesicles directly into the joints of aged mice significantly protected against cartilage degradation compared to pre-exercise control vesicles. This data maps a direct molecular route from aerobic exertion to joint preservation.

Actionable Insights

Consistent moderate aerobic exercise generates therapeutic biological nanoparticles capable of repairing aged cartilage. The intervention requires a sustained 3-month commitment to moderate-intensity aerobic work to produce circulating extracellular vesicles with joint-protective qualities. For individuals suffering from age-related joint degradation, this provides a physiological rationale for prioritizing aerobic training to protect avascular tissues.

The practical magnitude of this intervention is significant. In human cellular models, chondrocytes treated with post-exercise vesicles showed a roughly 66 percent absolute increase in cellular roundness (FormFactor increasing from approximately 0.3 to 0.5) compared to pre-exercise controls. This effectively reversed the pathological shape changes induced by aged tissue stiffness. In living aged mice, intra-articular injection of these post-exercise vesicles reduced the Osteoarthritis Research Society International severity scores from an average of 14 down to approximately 6. This 8-point absolute reduction represents a relative decrease in osteoarthritis severity of over 50 percent compared to control injections. This translates to a massive effect size (estimated Cohen’s d > 1.0) in delaying joint tissue degradation.

Context and Source

  • Paywalled Paper: Exercise enhances aged chondrocyte health through microRNA-29-enriched extracellular vesicles, Published: 29 September 2026.
  • Institution: Discovery Center for Musculoskeletal Recovery, Spaulding Rehabilitation Hospital, Harvard Medical School, USA.
  • Journal Name: Nature Aging.
  • Impact Evaluation: The impact score of this journal is 16.6, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.

RapAdmin

This perspective paper details the critical role of active vitamin D (1,25-dihydroxyvitamin D3) in maintaining thymic health, preventing premature immune aging, and establishing central tolerance. The authors synthesize recent findings showing that vitamin D signaling upregulates the autoimmune regulator (AIRE) in the thymus, which is necessary for the deletion of autoreactive T cells. Furthermore, disruptions in vitamin D signaling in murine genetic models lead to severely accelerated thymic involution, highlighting a potentially crucial mechanism for extending human healthspan by preserving naïve T cell output and mitigating age-related chronic inflammation.

The thymus is the biological clock of the immune system. It is uniquely responsible for the development and maturation of T cells, which are central to adaptive immunity. T cells undergo a rigorous selection process in the thymus to ensure they can recognize foreign pathogens without attacking the host tissues. This process of central tolerance relies on the presentation of tissue-restricted antigens by medullary thymic epithelial cells. If a developing T cell binds too strongly to a self-antigen, it is triggered to undergo apoptosis. The transcription factor AIRE drives this expression of self-antigens. Without functional AIRE, organisms develop devastating multiorgan autoimmunity.

Recent investigations reveal that vitamin D is not simply a bystander in this process but an essential coactivator. The biologically active form of vitamin D binds to the vitamin D receptor within thymic epithelial cells. This agonist-bound receptor then physically interacts with AIRE, recruiting it to chromatin to initiate the transcription of tissue-restricted antigens. Consequently, a deficiency in vitamin D signaling impairs this critical negative selection process, allowing highly self-reactive T cells to escape into the periphery and increasing the risk of autoimmune conditions.

Beyond establishing tolerance early in life, the thymus is notorious for being the first human organ to undergo aging-associated involution, beginning rapidly after adolescence. This involution involves tissue atrophy, declining cell counts, and adipocyte infiltration, leading to a marked drop in naïve T cell output. The resulting collapse in T cell receptor diversity weakens responses to new infections and cancer while contributing to the systemic chronic inflammation known as inflammaging.

Experimental models demonstrate that eliminating vitamin D signaling accelerates this thymic aging process drastically. Murine thymi lacking the enzyme necessary to synthesize active vitamin D exhibit disorganized tissue architecture, reduced expression of thymic longevity factors, and profound cellular depletion by early adulthood. Observational human data echo these principles, linking higher thymic health scores to reduced risks of cancer, metabolic disorders, and all-cause mortality. Ultimately, maintaining adequate vitamin D signaling emerges as a targeted strategy to support immune tolerance in youth and delay the immunological decline associated with aging.

Actionable Insights

For individuals seeking to optimize longevity and immune function, this research underscores the necessity of avoiding vitamin D deficiency, particularly during developmental windows. The epidemiological evidence strongly suggests that early-life vitamin D supplementation dramatically reduces the risk of autoimmunity. In a massive cohort study of over 10,000 children, regular vitamin D supplementation in infancy yielded a Relative Risk (RR) of 0.12 for developing Type 1 Diabetes compared to no supplementation. This constitutes an 88% relative risk reduction. Furthermore, dosing magnitude matters; infants receiving 2,000 IU/day exhibited an RR of 0.22 compared to those receiving lower doses, whereas infants presenting with clinical rickets faced a 3.0-fold increased relative risk of disease onset.

For adults focused on longevity, preserving thymic mass is paramount. The absolute effect size of vitamin D signaling on thymic aging in mammalian models is exceptionally large. By 26 weeks of age, mice lacking the ability to produce active vitamin D experienced a 90% collapse in thymic cell counts relative to their baseline at 4 weeks. In contrast, healthy control mice experienced only an 18% decline over the same period. This represents a 72% absolute difference in retained thymic cellularity. The practical take-home message is to routinely measure 25-hydroxyvitamin D levels and utilize supplementation to maintain clinical sufficiency to potentially slow immune system involution.

Context and Source

  • Title: Vitamin D signaling in thymic development and longevity., 14 September 2026.
  • Institution: McGill University.
  • Country: Canada.
  • Journal: Frontiers in Nutrition.
  • Impact Evaluation: The impact score of this journal is 4.0, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.

相关阅读:

RapAdmin

A longitudinal cohort study of Chinese older adults demonstrates that impaired kidney function is a significant, independent risk factor for cognitive decline. Evaluated through both estimated glomerular filtration rate and urinary albumin-to-creatinine ratio, the data show that renal dysfunction precedes and accelerates cognitive impairment. The findings strongly support the peripheral sink hypothesis, suggesting the kidneys are responsible for clearing neurotoxic proteins and that renal vascular damage mirrors cerebral microvascular degradation.

Dementia and cognitive decline are traditionally viewed exclusively through the lens of brain specific pathology. Neurologists focus on central nervous system aggregates of amyloid-beta and hyperphosphorylated tau proteins to explain the progression of Alzheimer’s disease and related dementias. However, the central nervous system does not operate in isolation. Peripheral organs are essential to the maintenance of brain homeostasis. This study pivots the focus to the kidneys, highlighting their crucial role in clearing systemic metabolic waste and neurotoxic proteins from the blood.

Researchers analyzed data from the Chinese Longitudinal Healthy Longevity Survey, tracking older adults to determine if baseline kidney function could predict future cognitive impairment. They utilized a dual parameter approach, measuring both the estimated glomerular filtration rate and the albumin-to-creatinine ratio. This methodology provides a comprehensive view of renal health, capturing both filtration capacity and endothelial vascular integrity.

The results from a three-year longitudinal follow-up present a compelling case for the kidney-brain axis. Older adults with impaired kidney function at baseline developed cognitive impairment at significantly higher rates than those with normal renal profiles. The physiological connection is twofold. First, the kidneys serve as a peripheral sink for amyloid-beta and tau. When glomerular filtration declines, these proteins accumulate systemically, cross the blood-brain barrier, and deposit in cerebral tissue. Second, the kidneys and the brain share unique microvascular architectures. The juxtamedullary afferent arterioles in the kidneys and the cerebral perforating arteries in the brain are both exposed to high pressure gradients. Consequently, elevated albuminuria serves as an early biomarker of systemic endothelial damage, reflecting simultaneously occurring microvascular degradation in the brain.

Interestingly, the study identified distinct thresholds where the risk of cognitive decline accelerates. The probability of cognitive impairment rises sharply once the estimated glomerular filtration rate drops below 61.55. Furthermore, this relationship exhibits a strong sex difference, with renal decline serving as a far more potent predictor of cognitive impairment in men than in women. These findings confirm that cognitive preservation requires a systemic approach. Maintaining renal filtration capacity and vascular integrity is not merely about preventing kidney disease; it is a fundamental requirement for long term cognitive health.

Actionable Insights

For longevity optimization, the primary directive is to treat kidney function biomarkers as leading indicators for brain health. Routine blood panels must track estimated glomerular filtration rate and albumin-to-creatinine ratio as aggressively as lipid profiles.

The practical magnitude of this intervention is substantial. Participants with impaired kidney function experienced a 22.95 percent cumulative incidence of cognitive impairment over just three years, compared to 9.15 percent in those with normal function. This represents an absolute risk increase of 13.8 percent and a relative risk increase of approximately 150 percent. The number needed to harm is roughly 7.2, meaning for every seven older adults who allow their kidney function to drop into the impaired range, one additional person will develop cognitive impairment within three years. Furthermore, elevated albuminuria resulted in a 2.65 times higher odds of incident cognitive decline.

To mitigate these risks, target an estimated glomerular filtration rate well above the critical risk inflection point of 61.55. Control systemic blood pressure rigorously to prevent the sheer-stress endothelial damage that causes albuminuria. Interventions that support vascular endothelial health and reduce systemic inflammation will dually protect renal filtration and cerebral microvasculature.

Context/Source

相关阅读:

RapAdmin

Rhesus macaques that breathed hazardous wildfire smoke for about nine days as infants, during Oregon’s 2020 Labor Day fires, still showed measurable immune differences four years later. Compared with colony-mates who missed the smoke, their blood cells produced roughly half to two-thirds less inflammatory signal when challenged with a bacterial toxin, their killer T cells had shifted from a “fresh reserve” state toward a “battle-worn” state, and their DNA methylation patterns leaned slightly toward those of older animals.

In September 2020, smoke from the Labor Day wildfires settled over the Oregon National Primate Research Center. Fine particle pollution peaked at around 273 micrograms per cubic meter, roughly twenty times the normal local maximum, and stayed in the “unhealthy” range for about a week. Fifteen infant macaques living in open-air enclosures, all under three months old, breathed it in. That age window matters: in rhesus monkeys it corresponds to about the first year of human life, when the immune system is still being assembled.

Four years later, researchers at Oregon Health and Science University drew blood from those animals, now late adolescents, and from eight comparison animals that were either born after the fires or kept in a filtered indoor facility. They then ran the cells through a battery of modern tests: cytokine panels, single-cell gene expression, and genome-wide DNA methylation.

Three findings stand out.

First, the exposed animals’ immune cells responded weakly to a mock bacterial infection. When stimulated with lipopolysaccharide, a bacterial wall component, their cells released markedly less IL-6, TNF-alpha and other alarm signals. The effect was clearest in males. This matches an earlier report from monkeys exposed to California wildfire smoke in 2008, which makes it more believable.

Second, the T cell compartment looked older than it should. In the comparison animals, roughly 44 percent of CD8 “killer” T cells were still naive, meaning uncommitted and available for new threats. In the smoke-exposed animals that figure was about 15 percent, with a matching rise in fully differentiated effector memory cells. The animals exposed at the youngest ages showed the largest shift. A distinct population of cytotoxic cells, almost absent in the comparison group, also appeared in some exposed animals.

Third, the epigenome carried a faint aging signature. An epigenetic clock estimated the exposed animals as 0.8 years older than expected, though that result did not reach statistical significance and sits within the clock’s own error margin. A second analysis found that about two-thirds of age-sensitive DNA sites had moved in the “older” direction.

What the study cannot tell us is whether any of this matters for health. No infections, vaccine responses, lung function or disease outcomes were measured. A dampened inflammatory response could mean vulnerability to infection, or it could be a harmless or even protective adaptation. The authors acknowledge they do not know which.

There are also reasons for caution about cause and effect. The exposed animals were about four months older at blood draw, were born in a different season, and half of the comparison group may have been exposed to the same smoke in the womb. The study does not report whether the groups differed in common viral infections that are known to reshape T cells.

Still, the central message is hard to dismiss: one short, severe smoke episode in infancy was followed, years later, by an immune system that looks different across several independent measurements.

Actionable Insights

This paper tested an exposure, not a treatment, so it offers nothing adults can take or do to reverse anything. Its practical message is about prevention for the youngest children.

The size of the differences was large by biological standards. Exposed animals released about 55 to 65 percent less IL-6 and TNF-alpha after a bacterial challenge. Their share of naive killer T cells was roughly one-third of the comparison group’s (about 15 percent versus 44 percent). In plain terms, a typical exposed animal fell outside the normal range of the unexposed group on that measure. The epigenetic age difference (0.8 years, roughly 19 percent of the animals’ age) was not statistically reliable.

Practical takeaways, all precautionary:

  1. Treat infants under one year as the highest-priority group during smoke events. The youngest animals showed the largest changes.
  2. During “unhealthy” air days (PM2.5 above about 55 ug/m3), keep infants indoors with windows closed and run a HEPA purifier sized for the room.
  3. Consider temporary relocation during multi-day severe smoke. Masks are not suitable for infants.
  4. Do not assume harm has occurred in an exposed child. No disease outcomes were shown.

Context/Source

相关阅读:

RapAdmin

A 35-year longitudinal cohort study from Norway reveals that individuals reporting mental health impairments in their 30s and 40s experience significantly higher levels of physical frailty after age 70. Using two distinct frailty models, researchers found that early midlife psychological distress nearly doubles the relative risk of becoming physically frail in older adulthood. These findings underscore the necessity of treating mental health as a core component of biological aging and longevity optimization, rather than a separate psychological phenomenon.

Psychological health is inextricably linked to physical durability. The HUNT study tracked over 27,000 Norwegians for more than three decades to determine if self-reported mental health impairment in midlife accelerates the accumulation of physical deficits in later life. The data reveals that psychological distress is not merely a transient emotional state but a physiological exposure that accelerates the deterioration of multiple somatic systems. By evaluating individuals through both the Fried physical frailty phenotype and the 35-item HUNT4 Frailty Index, the researchers demonstrate a persistent structural decline in physical capacity.

The biological toll observed in this study likely represents an underestimation (i.e. things are even worse than they are presented). The data exhibits a massive survivor bias. Mortality prior to the follow-up assessment at age 70 was 55.5 percent for individuals who reported early midlife mental health problems, compared to only 36.6 percent for those who did not. This indicates that the participants with a history of mental health challenges who survived to be tested at age 70 represent only the most robust fraction of that initial cohort. Even within this resilient subset, the differences in physical deterioration were profound.

Mental health impairment in early midlife drives a systemic erosion of physical reserves that is detectable over 35 years later. The associations remained robust even after adjusting for traditional lifestyle confounders like physical activity, obesity, smoking, and alcohol consumption. This strongly suggests that psychological distress exerts direct pathogenic effects on physical aging independent of behavioral coping mechanisms. Clinicians and researchers focused on lifespan extension must integrate proactive psychological monitoring and interventions into standard physiological health protocols. Treating depression, chronic stress, and anxiety is a structural necessity for maintaining late-life musculoskeletal and functional independence.

Actionable Insights

Midlife mental health impairment exerts a biological cost equivalent to decades of accelerated aging. For adults aged 35 to 49, reporting psychological distress resulted in an absolute increase of 0.066 on the Frailty Index by age 70. Because the Frailty Index typically increases by approximately 0.03 per decade in older adults, this 0.066 penalty is roughly equivalent to two additional decades of biological deficit accumulation.

The practical outcome is a severe loss of functional independence. At age 70, the prevalence of being categorized as physically “robust” dropped from 51 percent in the unexposed group to only 25.7 percent in the group with prior mental health problems. The prevalence of overt frailty doubled from 8.9 percent to 18.5 percent.

To optimize longevity, psychological stress and mental health disorders must be treated with the same aggressive intervention strategies used for hyperlipidemia or insulin resistance. Relying solely on physical exercise and diet is insufficient if the central nervous system remains in a state of chronic distress. Implementing cognitive behavioral therapy, prioritizing stress management protocols, and seeking psychiatric care are mandatory steps to prevent accelerated sarcopenia and loss of mobility in later life.

Context/Source

  • Open Access Paper: Midlife mental health and frailty up to 35 years later: Insights from the HUNT study
  • Institution: The Norwegian National Centre for Ageing and Health, Vestfold Hospital Trust, University of Oslo
  • Country: Norway
  • Journal: Archives of Gerontology and Geriatrics
  • Impact Evaluation: The impact score of this journal is 4.0, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

相关阅读:

RapAdmin

Researchers recorded 2,928 Spanish speakers in five Latin American countries and trained a model to guess each person’s age from how they spoke. The difference between guessed and real age, called the speech age gap (SAG), was larger in people with Alzheimer’s disease and frontotemporal dementia than in healthy volunteers. It tracked moderately with MRI-based brain age and weakly with plasma p-Tau217, three DNA methylation clocks and social disadvantage. The model misses true age by about 9 years on average. It is a research instrument, not a screening test.

Aging clocks estimate how old a body looks compared with its birth certificate. Most need blood or a brain scan, which keeps them out of the low-income regions where dementia is rising fastest. A consortium led from the Latin American Brain Health Institute in Chile asked whether a few minutes of recorded speech could do a similar job.

The logic is reasonable. Speaking draws on memory, attention, emotion and fine motor control at the same moment. Slower speech, longer pauses, flatter pitch and vaguer word choice are all known features of aging and dementia.

Participants narrated a short film, named animals and vegetables against the clock, listed words beginning with a set letter, and retold a short story twice. Software extracted more than 700 measurements and condensed them into seven scores covering timing, pitch, emotional tone, word choice and verbosity. A machine-learning model then predicted each person’s age.

As a clock, it is loose. The model explained 44 percent of the variation in age and missed by 9 years on average, in a cohort where most people were between about 54 and 76.

The gap still separated groups. Take one healthy volunteer and one patient at random, and the patient had the older-sounding speech between two-thirds and nearly nine-tenths of the time, depending on diagnosis. Language-dominant frontotemporal dementia, which attacks language directly, showed the largest gaps. The pattern held after matching for age, sex and education.

The most persuasive check came from MRI. Speech age gap explained roughly a fifth to a quarter of the variation in brain age gap, including within healthy volunteers. Links to the blood tau marker and to epigenetic clocks were far weaker, at about 4 percent of variation.

Three problems limit what can be concluded. First, the story-retelling task feeds both the speech clock and the memory score it is validated against. Someone who recalls less says less, so part of that correlation is one performance counted twice.

Second, education shaped the speech features more than any other background factor, and in healthy volunteers larger gaps tracked social disadvantage. Older-sounding speech may partly reflect fewer years of schooling instead of faster biological aging.

Third, the promise of cheap, scalable testing was not tested. Recordings were made in quiet rooms by neuropsychologists using studio-grade recorders, and transcripts were corrected by hand. Nothing was collected remotely, in conversation, or in another language.

There is also an undeclared interest. The paper states no competing interests, yet a corresponding author created the speech-analysis toolkit used here, which operates as an investor-backed startup.

Speech carries a signal that differs in dementia and echoes brain imaging. Whether it predicts anyone’s future remains unknown.

Actionable Insights

No intervention was tested, so it cannot say whether exercise, diet, drugs or cognitive training would change a speech age gap, or whether changing it would matter.

The size of the effects explains why. The model’s average error was 9 years, which is larger than the typical difference it found between patients and healthy people. A single person’s reading is therefore uninformative. At the group level, a patient sounded older than a healthy volunteer 66 to 88 percent of the time, where 50 percent would be a coin flip. That is a real difference between groups, but the paper gives no false-positive or false-negative rates, so its value for screening is unknown.

The agreement with blood markers was small. Speech gap explained about 4 percent of the variation in p-Tau217 and in epigenetic age, and 18 to 28 percent of MRI brain age gap.

Practical points:

  • Be skeptical of any app offering a “voice age” on the strength of this study.
  • Speaking more languages was not shown to help. The association was tiny and not statistically significant.
  • A noticeable change in word-finding or fluency deserves a clinical evaluation. That advice predates this paper.

Context and Source

  • Open Access Paper: Speech clocks decode dementia phenotypes, social exposome, and biological aging
  • Lead institutions: Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Chile; Cognitive Neuroscience Center, Universidad de San Andrés, Argentina
  • Journal: Science Advances (AAAS), published 30 September 2026
  • Impact evaluation: The impact score of this journal is 13.9 (Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

相关阅读:

RapAdmin

Researchers led from the MRC Laboratory of Medical Sciences in London tested compound 991, a drug that binds and activates the energy-sensing enzyme AMPK directly, in fission yeast, nematode worms and fruit flies. All three lived longer at the right dose, and the benefit vanished in yeast and worms lacking AMPK. They gave nanoparticle-packaged 991 by injection for three weeks and reported liver protein changes they describe as pro-longevity. The work is a clean proof of principle for AMPK as a drug target in invertebrates and an invitation to run mouse lifespan studies.

For two decades, AMPK has been one of the most talked-about targets in aging biology. The enzyme works like a cellular fuel gauge: when energy runs low, it switches on fat burning and recycling programs and dials down costly growth. Animals engineered to have more active AMPK tend to live longer. The trouble has been proving that a drug can do the same thing.

Metformin, the usual stand-in, is a poor test. It activates AMPK only indirectly, by mildly stressing mitochondria, and it hits many other targets. In worms and flies, its lifespan effects even run through gut bacteria rather than the animal itself. So a positive metformin result says little about AMPK, and a negative one says little either.

The new study in Aging Cell takes the direct route. Compound 991 slots into a pocket on the AMPK protein itself and turns the enzyme on. The team first showed that this pocket is conserved from humans down to yeast, and that 991 activates fly and worm AMPK at concentrations roughly a thousand times lower than metformin requires.

Then came the survival experiments. Female fruit flies fed a low dose lived about 9 percent longer at the median. Worms lived roughly 18 to 20 percent longer on two different bacterial diets, which argues against a microbiome explanation. Fission yeast cultures also survived longer. Flies and worms carried less fat, and flies ate just as much as untreated animals, so this was not accidental dieting.

The most persuasive experiment is the genetic control. In yeast and worms with the AMPK gene deleted, 991 did nothing for lifespan. That is strong evidence the drug works through its intended target.

The mouse section is the weakest part. Three mice per group received intravenous nanoparticles for three weeks, and their liver proteins shifted in ways consistent with AMPK activation: more mitochondrial machinery, less general protein synthesis. The authors call this a pro-longevity signature. No mouse lived a day longer in this study, because lifespan was not measured.

There is also a safety question the paper leaves largely unaddressed. A related, more drug-like AMPK activator from Merck caused heart enlargement in rodents and monkeys. Chronic, whole-body AMPK activation may not be benign, so a pulsatile approach may be necessary.

The bottom line: this is the cleanest pharmacological evidence so far that turning on AMPK itself can extend life in simple organisms. Whether that holds in a mammal remains untested.

Actionable Insights

Compound 991 is a laboratory tool with poor absorption in mammals and known toxicity, which is why the mouse work needed nanoparticle packaging and injections.

The real-world magnitude was modest. In flies, the best dose added about 7 days to a 76-day median lifespan, roughly 9 percent. In worms, about 2.5 to 3 days on a 14-day median, roughly 18 to 20 percent. These figures cannot be converted into human years. Most interventions that work in worms and flies shrink or disappear in mice.

Three practical lessons do carry over:

  1. More is not better. The dose that helped flies most was the lowest tested for lifespan. Higher doses helped less, then harmed. Anyone stacking multiple AMPK-activating compounds should take that seriously.
  2. This paper does not validate metformin or berberine for longevity. Its premise is that indirect activators are too messy to interpret.
  3. Exercise and periods without food remain the only well-established, low-risk ways to activate AMPK in humans.

Watch for mouse lifespan trials of second-generation direct activators.

Context and Source

  • Open Access Paper: Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies
  • Lead institutions: MRC Laboratory of Medical Sciences and Imperial College London, United Kingdom
  • Collaborating institutions: University of Cologne (CECAD and CMMC), Germany; Queen Mary University of London and The Francis Crick Institute, United Kingdom; Universite Claude Bernard Lyon 1, France
  • Journal: Aging Cell (Wiley, for the Anatomical Society), 2026
  • Impact evaluation: The impact score of this journal is 7.1 (Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

相关阅读:

RapAdmin

This narrative review from Kunming argues that type 2 diabetes behaves like accelerated aging and asks whether eight classes of glucose-lowering drugs could slow aging itself. Metformin has the broadest mechanistic evidence, SGLT-2 inhibitors and GLP-1 receptor agonists have the best human outcome data, and acarbose has the most reproducible mouse lifespan data.

For two decades, metformin has been the poster child of the idea that a cheap diabetes pill might slow aging. A new review in Pharmacological Research widens the lens to every major class of glucose-lowering drug and asks which, if any, deserve the label “geroprotector.”

The starting premise is that type 2 diabetes looks like aging on fast-forward. People with diabetes show shorter telomeres, more senescent cells, more chronic inflammation and failing mitochondria. In UK Biobank imaging data, diabetic brains appeared about two years older than expected. Muscle is lost roughly 40 percent faster. If high glucose and high insulin drive the same damage pathways as aging, drugs that relieve that pressure might slow aging more broadly.

The review then ranks the candidates. Metformin has the widest mechanistic footprint, touching AMPK, mTOR, autophagy, inflammation and the gut microbiome, plus one eye-catching monkey study. SGLT-2 inhibitors such as empagliflozin and dapagliflozin bring proven heart and kidney protection and mimic some features of fasting. GLP-1 drugs such as semaglutide reduce inflammation and may protect the brain. Acarbose, an old drug that blunts the glucose spike after starchy meals, has the most reproducible lifespan extension in mice.

The human trial section is where the data has lagged. In a randomized trial of older adults with frailty or sarcopenia, metformin did not improve walking speed, grip strength or frailty, and many participants tolerated it poorly. Another trial found metformin blunted the mitochondrial gains older adults normally get from aerobic exercise. For dementia, observational data and pooled trial data hint at 33 to 45 percent lower risk with GLP-1 drugs and SGLT-2 inhibitors in people with diabetes.

The authors’ own conclusion is, despite strong pre-clinical support, translational relevance remains uncertain due to model heterogeneity, limited randomized clinical evidence, and insufficient long-term follow-up. Clarifying tissue specificity, timing, dose, and patient selection will be essential for determining whether anti-diabetic agents can be safely repurposed as gerotherapeutics.

Actionable Insights

  1. Keep glucose in check. This is the best-supported lever. In UK Biobank data cited by the review, diabetes was linked to a brain that looked about 2.0 years older, versus 0.2 years for prediabetes, and a healthy lifestyle shrank the gap. Newly diagnosed diabetes was tied to 68 percent faster cognitive decline over four years.
  2. Protect muscle. People with diabetes lost about 0.24 kg of muscle per year versus roughly 0.17 kg in non-diabetics. That works out to about 1.1 kg of extra loss over 16 years.
  3. Do not assume metformin helps healthy older adults. The MET-PREVENT trial showed no functional benefit, and a separate trial showed blunted exercise adaptations.
  4. If you have diabetes, the choice of drug may matter for the brain. GLP-1 drugs were associated with 45 percent lower odds of dementia in pooled trials, and SGLT-2 inhibitors with a 43 percent lower rate in observational data. These are relative figures. Absolute benefits are probably much smaller, and the data are indirect.
  5. Dapagliflozin’s heart failure benefit is real even without diabetes. In DAPA-HF, as I recall the published result, about 5 fewer patients per 100 had an event over 18 months.
  6. Acarbose’s mouse data are interesting. See more here: Acarbose - Details On Another Top Anti-Aging Drug

Context and Source

  • Open Access Paper: Geroprotective potential of anti-diabetic medications: Bridging type 2 diabetes and accelerated aging, Sept. 2026
  • Institutions: Second Affiliated Hospital of Dali University (Third People’s Hospital of Yunnan Province), and the Kunming Institute of Zoology, Chinese Academy of Sciences
  • Country: China
  • Journal: Pharmacological Research, online 8 September 2026
    Impact evaluation: The impact score of this journal is approximately 10.8, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

Four cardiologists at Saint Luke’s Mid America Heart Institute argue that SGLT inhibitors (dapagliflozin, empagliflozin and relatives) are the most credible geroprotector now available, ahead of rapamycin and metformin. They pool 13 placebo-controlled outcome trials covering 90,413 patients and find a 12% relative reduction in death from any cause and a 10% reduction in first hospitalization. They then add mouse lifespan data, genetic studies and proposed fasting-mimicking mechanisms.

For a decade, SGLT inhibitors have been the quiet success story of cardiology. Designed to lower blood sugar by making the kidneys dump glucose into urine, they turned out to keep heart failure patients out of hospital and slow kidney decline, whether or not the patient had diabetes. A new review asks whether the class is doing something more basic: slowing aging itself.

The argument runs like this. Blocking the SGLT2 transporter sends 60 to 80 grams of glucose a day out in the urine, around 240 to 320 calories. Insulin falls, glucagon rises, and blood ketones climb from about 0.1 to 0.3 to 0.6 millimoles per liter. The body, the authors propose, reads this as mild fasting. In animal and cell experiments that state activates the energy sensor AMPK, quiets the growth pathway mTOR and increases autophagy, the cell’s recycling system. These are the same pathways targeted by calorie restriction and rapamycin.

What separates this class from other longevity candidates is human outcome data. Pooling 13 large trials, the authors calculate a hazard ratio for death of 0.88. In their model, 9.6% of placebo patients died within three years against 8.5% on the drug. First hospitalization for any reason fell from 29.8% to 27.2%. They also cite a genetic study in which people who carry variants that mimic lifelong SGLT2 inhibition had 22% lower all-cause mortality, and a National Institute on Aging mouse study in which canagliflozin extended median lifespan by 14% in males.

There are large caveats. Every trial participant was already ill, with an average risk of death many times that of a healthy 50-year-old. Preventing deaths in people with failing hearts and kidneys is what a good cardiorenal drug does, and it is not the same as slowing aging. The benefit in heart failure appears within weeks, which is far too quick for any change in the rate of aging and points instead to effects on fluid balance and cardiac workload. The mouse result held only in males, and a later study from the same program found that female mice started on the drug in midlife died sooner.

The paper is also a narrative review, not a systematic one. It appears in the first issue of a brand-new journal that does not yet have an impact factor or confirmed indexing. Its scorecard ranking SGLT inhibitors above rapamycin and metformin was graded by the authors themselves.

Insights

Assuming the same 12% relative benefit carries over (unproven), a 50-year-old with a yearly death risk near 0.4% would see about 700 people treated for three years to prevent one death. By comparison, genital yeast infections occur in roughly 6 in 100 women and 2 in 100 men.

Practical points from the paper:

  • The dose used for heart and kidney benefit is 10 mg daily of dapagliflozin or empagliflozin.
  • Generic dapagliflozin now costs about $25 to $55 for 90 days in the US.
  • Stop the drug during prolonged fasting, very-low-carbohydrate dieting, heavy drinking, severe illness and before surgery, because of the risk of ketoacidosis. This matters for anyone combining it with fasting or keto protocols.
  • Canagliflozin is the SGLT2 inhibitor with the best mouse lifespan data.

Context/Source

相关阅读:

RapAdmin

A retrospective analysis of US electronic health records compared about 417,000 adults aged 50 and over who had a diagnosed voice disorder with matched adults who had a routine check-up. Those with a voice disorder were 29 percent more likely to later be diagnosed with mild cognitive impairment, Alzheimer’s disease or dementia. The figure was 58 percent for voice disorders without hearing loss and roughly double for voice disorders with hearing loss. The authors argue voice disorders may be a stronger early marker than hearing loss. The data are observational, absolute risks are small, and the paper does not test whether treating the voice changes anything.

Hearing loss has spent the past decade as the headline modifiable risk factor for dementia. A team at Drexel University College of Medicine in Philadelphia now proposes that the other half of conversation, the voice, deserves similar attention.

Using TriNetX, a platform that pools anonymized records from US health systems, the researchers identified adults aged 50 and over who received a first diagnosis of dysphonia, aphonia or a related voice disorder between 2016 and 2026. Each was paired with a similar person whose index visit was a general medical exam. Pairs were matched on age, sex, race, ethnicity and six cardiovascular risk factors. Anyone with existing dementia, Parkinson’s disease, stroke, multiple sclerosis or ALS was excluded, and the first year after diagnosis was ignored to reduce the chance that the voice problem was simply an early symptom of something already underway.

Across 833,417 people, a voice disorder was associated with a 29 percent higher rate of later cognitive diagnoses. Hearing loss, run through the same pipeline in 3.3 million people, came out at 27 percent. When the voice group was split, people with a voice disorder and no recorded hearing loss had a 58 percent higher rate than their controls, and those with both conditions had roughly twice the rate.

The authors offer two explanations. The first is that the voice is an early casualty of brain disease. In Parkinson’s disease, abnormal protein deposits appear in the brainstem nuclei of the vagus nerve, which controls the larynx, years before tremor begins. The second is social. People who struggle to be heard may withdraw from conversation, and reduced social engagement is itself linked to dementia.

The appeal is practical. Voice diagnoses already sit in medical records, so no new test is needed to find these patients.

The caveats are substantial. The paper reports no event counts. Its survival curves suggest that only about 1.5 percent of controls received a cognitive diagnosis over ten years, far below what population studies find at this age, which implies many cases were never coded. In that setting, people who see more specialists are more likely to have a memory problem noticed and recorded. The matching ignored education, depression, alcohol, reflux, lung disease and how often people visit doctors.

The claim that voice beats hearing loss rests on subgroups compared against different control populations. The paper’s own forest plot appears to show no significant difference between the full voice cohort and the hearing loss cohort.

The finding is a plausible, hypothesis-generating signal that a persistent voice change in later life may travel with elevated neurological risk. It is not evidence that voice problems cause dementia, or that voice therapy prevents it.

Actionable Insights

  1. Persistent hoarseness deserves a medical look regardless of this paper. Existing ENT guidance recommends examining the larynx when a voice change lasts beyond about four weeks, mainly to rule out cancer, nerve injury and neurological disease.
  2. Keep the size of the risk in proportion. Relative increases of 29 to 104 percent sound large, but the baseline is low. If about 15 in 1,000 matched controls received a cognitive diagnosis over ten years (my reading of the paper’s curves), then a voice disorder corresponds to roughly 19 in 1,000, voice disorder without hearing loss to about 24, and voice plus hearing loss to about 30. That is 4 to 15 extra diagnoses per 1,000 people over a decade. Converted to a standardized scale, these are small effects (Cohen’s d of roughly 0.14 to 0.39, where 0.2 is conventionally “small”).
  3. There is no evidence here that voice therapy protects the brain. The study did not examine treatment.
  4. Use a late-life voice change as a prompt to check better-supported dementia risk factors: hearing, blood pressure, LDL cholesterol, diabetes, physical activity and social contact.
  5. If you have both a voice disorder and hearing loss, a baseline cognitive screen is a reasonable, low-cost conversation to have with a clinician.

Context/Source

  • Open Access Paper: Voice Disorders as Early Biomarkers of Cognitive Decline
  • Institution: Drexel University College of Medicine, Department of Otolaryngology Head and Neck Surgery, Philadelphia
  • Country: United States
  • Journal: Journal of Voice (Elsevier, on behalf of The Voice Foundation)
  • Impact evaluation: The impact score of this journal is approximately 2.4, evaluated against a typical high-end range of 0–60+ for top general medical and science journals, therefore this is a Low impact journal. Within its niche it is mid-ranked.